Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Has been diagnosed with high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, confirmed by a tissue test
- Has cancer that can be measured on a scan
- (For certain groups) Has cancer that came back after 1 to 3 previous treatments, and scans show the cancer got worse 6 months or more after the last platinum-based chemotherapy (known as "platinum-sensitive" disease)
- (For certain groups) Has cancer that came back after 1 to 3 previous treatments, and scans show the cancer got worse in less than 6 months after the last platinum-based chemotherapy (known as "platinum-resistant" disease), and has received no more than 1 previous treatment containing bevacizumab
- (For certain groups) Is considered suitable to receive a drug called bevacizumab as part of treatment
- (For certain groups) Has cancer that came back after 1 previous treatment, is platinum-sensitive (see above), and previously received a type of drug called a PARP inhibitor during first-line treatment
- Has provided a fresh tissue sample (biopsy) from a tumor that has not been treated with radiation
- Is in good general health, able to carry out normal daily activities with little or no limitation, as assessed within 7 days before joining the trial
- If living with HIV, has the virus well controlled with anti-HIV medication
- If positive for hepatitis B, has been on antiviral treatment for at least 4 weeks and has no detectable hepatitis B virus before joining the trial
- If previously infected with hepatitis C, has no detectable hepatitis C virus at the screening stage
Who may not be able to join:
- Had a stroke, mini-stroke, or other blood clot in an artery within the 6 months before joining the trial
- Has serious or uncontrolled heart or blood vessel disease
- Has severe lung problems caused by an ongoing lung condition, an autoimmune or inflammatory disease affecting the lungs, or has had a lung removed
- Has moderate or severe nerve damage causing numbness, tingling, or pain, particularly in the hands or feet (confirm with trial site)
- Has previously been treated with a therapy that targets a protein called cadherin-6
- Has received any anticancer treatment (including experimental treatments) within 4 weeks or 5 half-lives (whichever is shorter) before joining the trial
- Has had radiotherapy within 2 weeks of starting the trial, or still has side effects from radiation that require steroid medication
- Is currently taking steroid medication on a long-term, ongoing basis
- Has another cancer that is growing or has needed active treatment within the past 3 years
- Has active cancer that has spread to the brain or the lining of the brain
- Has any history of a lung condition called interstitial lung disease or pneumonitis, currently has it, or it cannot be ruled out by scans at screening
- Has an active infection that requires treatment with medication
- Is living with HIV and has a history of Kaposi's sarcoma or a condition called Multicentric Castleman's Disease
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Merck Sharp & Dohme LLC
Phone: 1-888-577-8839
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0); Part 1: Number of Participants with One or More Adverse Events (AEs); Part 1: Number of Participants who Discontinue Study Intervention Due to an AE; Part 2: Objective Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.